Anti-MR-Pro ADM antibody, Mouse monoclonal

Anti-MR-Pro ADM antibody, Mouse monoclonal (MidRegional pro-Adrenomedullin) (mouse IgG2a isotype) is derived from the hybridoma MR2.1 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to the internal region of human Adrenomedullin (ADM), conjugated to KLH. The precursor peptide of Adrenomedullin (ADM), prepro-ADM, is processed to the circulating form of ADM. During this processing, other peptides are also being generated; PAMP (proadrenomedullin N-terminal 20 peptide) with suggested hypotensive effect, and MR-pro ADM (Mid-Regional pro-Adrenomedullin) which consists of 47 amino acid-propeptide.

Synthetic peptide corresponding to the internal region of human Adrenomedullin (ADM), conjugated to KLH.

Anti-MR-Pro ADM antibody has been used in immunoblotting, immunohistochemistry.

MR-pro ADM (MidRegional pro-Adrenomedullin) has been suggested as a biomarker for plasma concentrations of Adrenomedullin as it is stoichiometrically generated and relatively stable in the plasma. Increased levels of MR-pro ADM were associated with an increased risk of mortality and morbidity in patients with heart failure, independent of natriuretic peptides. In dialysis patients MR-pro ADM and MR-pro ANP were shown to be associated with mortality in general and particularly with cardiovascular related mortality, with the highest risk when both parameters were elevated.

Solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide

ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.